Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from uniQure ( (QURE) ).
On November 3, 2025, uniQure announced a regulatory update regarding its investigational gene therapy for Huntington’s disease, AMT-130, following a pre-Biologics License Application meeting with the FDA. The company revealed that the FDA no longer agrees that data from Phase I/II studies of AMT-130 in comparison to an external control may be adequate for a BLA submission, creating uncertainty around the timing of the submission. Despite this setback, uniQure is committed to working with the FDA and other regulatory bodies to find a path forward for AMT-130’s approval, emphasizing the therapy’s potential benefits for patients with Huntington’s disease.
The most recent analyst rating on (QURE) stock is a Hold with a $67.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.
Spark’s Take on QURE Stock
According to Spark, TipRanks’ AI Analyst, QURE is a Neutral.
uniQure’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative profit margins. The technical analysis provides some positive signals, but potential overbought conditions warrant caution. Valuation metrics are unfavorable due to ongoing losses and lack of dividends. Despite promising clinical advancements, the financial instability remains a significant concern.
To see Spark’s full report on QURE stock, click here.
More about uniQure
uniQure N.V. is a leading gene therapy company focused on advancing transformative therapies for patients with severe medical needs. The company is known for its gene therapy treatments, including a historic approval for hemophilia B, and is developing a pipeline of therapies for conditions such as Huntington’s disease, refractory temporal lobe epilepsy, ALS, and Fabry disease.
Average Trading Volume: 3,245,497
Technical Sentiment Signal: Buy
Current Market Cap: $4.17B
See more insights into QURE stock on TipRanks’ Stock Analysis page.